For the quarter ending 2026-03-31, IOVA had $33,442K increase in cash & cash equivalents over the period. -$78,682K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 71,430 | 86,771 | - | - |
| Cost of goods sold (excluding depreciation and amortization) | 38,829 | 36,603 | - | - |
| Stock-based compensation | 1,019 | 1,309 | - | - |
| Royalties | 2,650 | 5,199 | - | - |
| Total cost of sales | 42,498 | 43,111 | - | - |
| Research and development | 57,370 | 65,531 | - | - |
| General and administrative | 18,699 | 12,251 | - | - |
| Sales and marketing | 15,116 | 19,314 | - | - |
| Depreciation and amortization | 8,539 | 9,517 | - | - |
| Restructuring charges | - | 0 | - | - |
| Other segment items | 8,253 | 8,951 | - | - |
| Total expenses | 107,977 | 115,564 | - | - |
| Net loss | -79,045 | -71,904 | -319,074 | - |
| Stock-based compensation expense | 11,269 | 11,817 | 11,900 | 37,858 |
| Unrealized foreign exchange loss | -434 | 373 | -232 | 97 |
| Amortization of intangible assets | 5,716 | 6,204 | 5,769 | 11,104 |
| Amortization of right of use asset | 1,876 | 2,716 | 2,922 | 5,747 |
| Depreciation and amortization of property and equipment | 2,823 | 3,724 | 2,986 | 6,152 |
| Deferred tax benefit expense | -665 | 184 | -2,405 | 150 |
| Excess and obsolescence reserve | -506 | 3,702 | 1,391 | 8,311 |
| Accretion of discounts and premiums on investments | 1,120 | 1,342 | 1,711 | 4,149 |
| Loss on asset disposals | -28 | 0 | 0 | -44 |
| Prepaid expenses, other assets and long-term assets | 1,466 | 661 | -2,776 | 10,138 |
| Trade accounts receivable | -690 | 15,687 | 6,823 | -9,402 |
| Inventory | 4,931 | 4,001 | 3,182 | 7,028 |
| Operating lease liabilities | -2,027 | -2,900 | -2,410 | -5,590 |
| Accounts payable | 15,888 | -5,213 | -4,393 | 2,945 |
| Accrued expenses and other liabilities | -21,038 | 21,169 | 5,499 | 1,969 |
| Net cash used in operating activities | -72,074 | -52,565 | -78,702 | -171,141 |
| Maturities of investments | 74,000 | 70,000 | 120,000 | 210,000 |
| Purchase of investments | 55,998 | 59,905 | 92,144 | 166,619 |
| Cash paid for acquisition, including contingent consideration, net of cash acquired | - | - | 0 | 0 |
| Purchase of property and equipment | 6,608 | 9,320 | 10,844 | 13,672 |
| Net cash provided by (used in) investing activities | 11,394 | 775 | 17,012 | 29,709 |
| Tax payments related to shares withheld for vested restricted stock units | 4,179 | 445 | 466 | 6,148 |
| Proceeds from the issuance of common stock under employee stock purchase plan | - | 839 | 2 | 669 |
| Proceeds from the issuance of common stock upon exercise of options | - | 0 | 0 | 15 |
| Proceeds from the issuance of common stock, net | 98,514 | 55,778 | 88,520 | 162,009 |
| Net cash provided by financing activities | 94,335 | 56,172 | 88,056 | 156,545 |
| Effect of foreign exchange rate changes | -213 | 577 | -680 | 1,247 |
| Net increase in cash, cash equivalents and restricted cash | 33,442 | 4,959 | 25,686 | 16,360 |
| Cash, cash equivalents and restricted cash beginning of period | 169,058 | 164,099 | 122,053 | - |
| Cash, cash equivalents and restricted cash end of period | 202,500 | 169,058 | 164,099 | - |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)